Larance, B and Degenhardt, L and Grebely, J and Nielsen, S and Bruno, R and Dietze, P and Lancaster, K and Larney, S and Santo, T and Shanahan, M and Memedovic, S and Ali, R and Farrell, M, Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia, Addiction pp. 1-11. ISSN 0965-2140 (2019) [Refereed Article]
|PDF (Published version)|
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, https://creativecommons.org/licenses/by-nc/4.0/ which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Aims: To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia.
Design: Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australia in November 2018. Setting Sydney, Melbourne and Hobart.
Participants: A total of 402 people who regularly use opioids interviewed December 2017 to March 2018.
Measurements: Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthly injections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosing setting, unsupervised doses, out-of-pocket expenses and travel distance).
Findings: Sixty-eight per cent [95% confidence interval (CI) = 6373%] believed XR-buprenorphine was a good treatment option for them. They were more likely to report being younger [2635 versus > 55 years; odds ratio (OR) = 3.16, 95% CI = 1.128.89; P = 0.029], being female (OR = 1.67, 95% CI = 1.042.69; P = 0.034), < 10 years school education (OR = 1.87, 95% CI = 1.123.12; P = 0.016) and past-month heroin (OR = 1.81, 95% CI = 1.152.85; P = 0.006) and methamphetamine use (OR = 1.90, 95% CI = 1.203.01; P = 0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% preferred weekly and 39% preferred monthly. Among OAT recipients (n = 255), believing XR-buprenorphine was a good treatment option was associated with shorter treatment episodes (12 versus ≥ 2 years; OR = 3.93, 95% CI = 1.26 12.22; P = 0.018), fewer unsupervised doses (≤ 8 doses past-month versus no take-aways; OR = 0.50; 95% CI = 0.27 0.93; P = 0.028) and longer travel distance (≥ 5 versus < 5 km; OR = 2.10, 95% CI = 1.203.65; P = 0.009). Sixtynine per cent reported no problems or concerns with potential differences in availability, flexibility and location of XRbuprenorphine.
Conclusions: Among regular opioid users in Australia, perceptions of extended-release buprenorphine as a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)convenience of current opioid agonist treatment.
|Item Type:||Refereed Article|
|Keywords:||buprenorphine depot, buprenorphine injection, depot preparations, medication-assisted treatment, patient preferences, opioiduse disorder|
|Research Group:||Applied and developmental psychology|
|Research Field:||Applied and developmental psychology not elsewhere classified|
|Objective Group:||Public health (excl. specific population health)|
|Objective Field:||Public health (excl. specific population health) not elsewhere classified|
|UTAS Author:||Bruno, R (Associate Professor Raimondo Bruno)|
|Web of Science® Times Cited:||13|
|Downloads:||4 View Download Statistics|
Repository Staff Only: item control page